D-47 | Ticagrelor versus Clopidogrel in Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention for Acute Coronary Syndrome in Chronic Kidney Disease
Dual antiplatelet therapy (DAPT) is the standard treatment post percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Although ticagrelor and clopidogrel are commonly used, data on their efficacy in chronic kidney disease (CKD) patients is scarce. We aimed to examine the outcomes of ticagrelor versus clopidogrel as DAPT in CKD patients using a multi-national data set.
Authors
- Qi Xuan Ang (ORCID: https://orcid.org/0000-0002-3996-3811)
- Min Choon Tan (ORCID: https://orcid.org/0000-0002-7682-8934)
- Justin Z. Lee (ORCID: https://orcid.org/0000-0003-2823-9243)
- Yong Hao Yeo (ORCID: https://orcid.org/0000-0001-5559-7236)
- Tanusha Winson
- Aravinthan Vignarajah (ORCID: https://orcid.org/0000-0002-3758-0024)
Institutions
- Cleveland Clinic (US)
- Sultan Abdul Halim Hospital (MY)
- Beaumont Health (US)
- Sparrow Hospital (US)
- AIMST University (MY)
- Saint Michael's Medical Center (US)
- Michigan State University (US)
Publication Details
- Journal
- Journal of the Society for Cardiovascular Angiography & Interventions
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jscai.2025.103179
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00